David Mazzo | Chief Executive Officer
Caladrius Biosciences

David Mazzo, Chief Executive Officer, Caladrius Biosciences

David J. Mazzo, PhD, was appointed as Caladrius' Chief Executive Officer and as a member of our Board of Directors on January 5, 2015. In addition, Dr. Mazzo was appointed as President of the Company in March 2017. Dr. Mazzo brings to the Company over 35 years of international experience in the pharmaceutical industry. Prior to joining Caladrius, Dr. Mazzo served from August 2008 to October 2014 as Chief Executive Officer and as a member of the board of directors of Regado Biosciences, Inc., a NASDAQ-listed biopharmaceutical company focused on the development of novel antithrombotic drug systems for acute and sub-acute cardiovascular indications. Prior to his leading Regado, from March 2007 to April 2008, Dr. Mazzo was President, Chief Executive Officer and a director of Æterna Zentaris, Inc., a publicly held international biopharmaceutical company. From 2003 until 2007, Dr. Mazzo served as President, Chief Executive Officer and a director of Chugai Pharma USA, LLC, a biopharmaceutical company which was the U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan, a member of the Roche Group of Switzerland. In his last position within big pharma, Dr. Mazzo was Senior Vice President and the head of global Development Operations at the Schering-Plough Corporation, a publicly held global pharmaceutical company that was subsequently acquired by Merck & Co., Inc. He was also a director of Schering?s Essex Chimie European subsidiary. Prior to that, Dr. Mazzo held executive positions at Hoechst Marion Roussel, Inc., the US subsidiary of Hoechst AG, which was subsequently acquired by Sanofi, a multinational pharmaceuticals company; and Rhone-Poulenc Rorer, Inc., a subsidiary of Rhone-Poulenc Sante SA, a French pharmaceuticals company, which was subsequently acquired by Hoechst AG. He also previously served on the Board of Directors of Avanir Pharmaceuticals, Inc., a biopharmaceutical company which was sold to Otsuka Holdings in 2015. He currently serves on the Board of Directors of both EyePoint Pharmaceuticals, (formerly known as pSivida Corp.) and Neuralstem, Inc., publicly held biopharmaceutical companies.  Dr. Mazzo earned a BA in the Honors Program (interdisciplinary humanities) and a BS in chemistry from Villanova University. In addition, Dr. Mazzo received his MS in chemistry and his PhD degree in analytical chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland.


Day 1: Wednesday 19th May 2021 - Cell Therapy @ 15:00

Caladrius Biosciences; Progress, challenges and learnings during the COVID-19 pandemic

  • CD34+ cell therapy platform yielding a multi-product development pipeline with 2 clinical programs having regenerative medicine “breakthrough” designation
  • Multiple potential value creating events in the next 12-24 months based on milestones across the pipeline
  • Strong balance sheet; ~$116 million in cash & investments (2/25/2021) with no debt and cash runway projected to fund operations for several years
last published: 10/May/21 08:45 GMT

back to speakers